Impact of Hydrophilic Corona Design on Telodendrimer Micelles: Fluorescence-Based Insights into Unimer Exchange

Marianne Ashford – Senior Principal Scientist, Advanced Drug Delivery, AstraZeneca; Richard England, PhD – Associate Principal Scientist, Advanced Drug Delivery, AstraZeneca; Anders Gunnarsson – Principal Scientist, Discovery Sciences, AstraZeneca; Robert Luxenhofer – Professor, Department of Chemistry, Helsinki University; Kevin Treacher – Principal Scientist, Pharmaceutical Technology and Development, AstraZeneca

Introduction: Chemotherapeutic agents often exhibit high toxicity and poor solubility that impact their efficacy in cancer treatment. Although various types of nanocarriers have been used in drug delivery, poor loading capacity and premature drug release remain the major challenges (1). Here, we address these challenges by developing a telodendrimer micelle with tuneable physicochemical properties to improve drug delivery outcomes (2).